The going-concern disclosure makes CLDI a high-risk holding. Traders should expect continued downward pressure as the company must raise dilutive capital or face liquidation. Avoid long positions until a material capital infusion or pipeline catalyst materializes. Short interest may already be limited due to tiny float — monitor for OTC delisting.
Price Chart
Executive Summary
Calidi Biotherapeutics disclosed an audit report with a going-concern emphasis in its 2025 Form 10-K, required by NYSE American Section 610(b). The company, with only a $4M market cap and no approved products, faces a material risk of inability to continue operations without additional capital, and its lead candidate CLD-401 is still in IND-enabling studies. This is a strong negative signal for a pre-revenue biotech with limited cash runway.
Key Facts
- Audit report on 2025 10-K includes a going-concern explanatory paragraph
- Lead candidate CLD-401 remains in IND-enabling studies — no near-term revenue
- Market cap is approximately $4M, indicating severe financial distress
- Forward-looking statements explicitly flag inadequate capital to support clinical trials
- Trading on OTC markets (no NYSE American listing gain) suggests non-compliance or delisting risk
Financial Impact
Going-concern qualification implies existential risk for this $4M market cap issuer; no revenue or earnings to quantify
Risk Factors
- Inability to raise sufficient capital to fund operations in the next 12 months
- NYSE American delisting likely (already trading OTC)
- Lead asset (CLD-401) is years from potential approval with high clinical risk
- Ultra-low market cap creates extreme volatility and liquidity constraints
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300394 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 8-K | $1.07 | awaiting T+20 | — | $0.6450 (+39.72%) |
Sep 22, 2026 4w ago | 8-K | $1.09 $0.7680 | ▲ +29.54% | ▲ +30.23% | $0.6450 (+40.83%) |
Sep 17, 2026 5w ago | 424B5 | $1.10 $0.8370 | ▲ +23.91% | ▲ +24.11% | $0.6450 (+41.36%) |
Aug 13, 2026 10w ago | 8-K | $1.59 $1.22 | ▼ −23.27% | ▼ −21.28% | $0.6450 (−59.43%) |
Aug 13, 2026 10w ago | Press Release | $1.59 $1.22 | ▼ −23.27% | ▼ −21.28% | $0.6450 (−59.43%) |
Jun 29, 2026 16w ago | 3 | $0.1700 $0.0933 | ▼ −45.12% | ▼ −42.80% | $0.6450 (+279.41%) |
May 26, 2026 21w ago | Press Release | $2.83 $2.51 | ▼ −11.30% | ▼ −9.24% | $0.6450 (−77.22%) |
May 22, 2026 22w ago | Press Release | $2.83 $2.51 | ▲ +11.30% | ▲ +9.24% | $0.6450 (+77.22%) |
Apr 20, 2026 27w ago | Press Release | $0.2500 $0.1830 | ▼ −26.80% | ▼ −31.00% | $0.6450 (+158.00%) |
Mar 27, 2026 30w ago | Press Release | $0.2390 $0.2240 | ▼ −6.28% | ▼ −18.87% | $0.6450 (+169.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers